Investor Relations - BioDelivery Sciences International (BDSI) http://bdsi.investorroom.com/ BioDelivery Sciences BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its First Quarter 2012 Financials http://bdsi.investorroom.com/index.php?s=43&item=48 Signed licensing agreement with Endo Pharmaceuticals for BEMA Buprenorphine for chronic pain worth up to $180 million plus royalties Thu, 10 May 2012 16:30:00 -0400 http://bdsi.investorroom.com/index.php?s=43&item=48 BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference http://bdsi.investorroom.com/index.php?s=43&item=47 Wed, 09 May 2012 07:00:00 -0400 http://bdsi.investorroom.com/index.php?s=43&item=47 BioDelivery Sciences Awarded Patent Resulting in $15 Million Milestone Payment http://bdsi.investorroom.com/index.php?s=43&item=46 Patent extends exclusivity protection for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone (BNX) through 2027 Tue, 17 Apr 2012 07:00:00 -0400 http://bdsi.investorroom.com/index.php?s=43&item=46 BioDelivery Sciences to Present at the Future Leaders in the Biotech Industry Conference http://bdsi.investorroom.com/index.php?s=43&item=45 Mon, 16 Apr 2012 08:00:00 -0400 http://bdsi.investorroom.com/index.php?s=43&item=45 BioDelivery Sciences to Host Opioid Dependence Investor Event and Webcast on April 11, 2012 http://bdsi.investorroom.com/index.php?s=43&item=44 Event will focus on the treatment of Opioid Dependence and the BNX development program Thu, 05 Apr 2012 08:00:00 -0400 http://bdsi.investorroom.com/index.php?s=43&item=44